News
VYGR
1.730
+1.76%
0.030
Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Voyager Therapeutics (VYGR)
TipRanks · 2d ago
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Voyager Therapeutics (VYGR)
TipRanks · 6d ago
Analysts’ Top Healthcare Picks: Voyager Therapeutics (VYGR), Evolent Health (EVH)
TipRanks · 6d ago
Weekly Report: what happened at VYGR last week (1102-1106)?
Weekly Report · 6d ago
Voyager Therapeutics price target lowered to $12 from $18 at Baird
TipRanks · 11/06 11:51
Voyager Therapeutics Reports Third Quarter 2026 Financial Results and $132 Million Cash Position
NASDAQ · 11/06 09:08
Voyager Therapeutics GAAP EPS of -$0.40 beats by $0.02, revenue of $4.01M misses by $2.34M
Seeking Alpha · 11/05 22:22
*Voyager Therapeutics 3Q Loss/Shr 40c >VYGR
Dow Jones · 11/05 21:01
Press Release: Voyager Reports Third Quarter 2026 Financial and Operating Results
Dow Jones · 11/05 21:01
Voyager Therapeutics: Q3 Earnings Snapshot
Barchart · 11/05 15:34
H.C. Wainwright Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
TipRanks · 11/05 11:36
Weekly Report: what happened at VYGR last week (1026-1030)?
Weekly Report · 11/02 09:51
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:44
H.C. Wainwright Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
TipRanks · 10/29 09:06
Weekly Report: what happened at VYGR last week (1019-1023)?
Weekly Report · 10/26 09:51
Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
Seeking Alpha · 10/23 21:19
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Pharming Group (PHAR) and BioNTech SE (BNTX)
TipRanks · 10/23 12:10
Voyager Appoints Robin Swartz As President, CEO Transition Expected In Q1 2027; Stock Down
NASDAQ · 10/21 15:02
Voyager Therapeutics Appoints Robin Swartz CEO
Dow Jones · 10/21 12:43
Voyager Therapeutics advances leadership transition amid Alzheimer’s focus
TipRanks · 10/21 12:28
More
Webull provides a variety of real-time VYGR stock news. You can receive the latest news about Voyager Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VYGR
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.